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Triple negative breast cancer is a distinct group of breast tumors that is 
characterized by the lack of expression of hormone receptors including estrogen (ER) 
and progesterone (PgR) receptors as well as human epidermal growth factor receptor 
2 (HER2). This subtype is a high risk breast cancer with the existence of breast 
cancer stem cells (BCSCs) which is presumed to be more aggressive and difficult to 
cure. In this in vitro study, the effect of cisplatin as a member of the platinum 
anticancer drugs in two different breast cancer cell lines, that represent the triple 
negative (MDA-MB-468) and hormone positive Luminal A (MCF-7) breast cancer 
subtypes were examined. Cisplatin was used at 5 different concentrations 5, 10, 15, 
20 and 25µM, and cell viability was measured using celltiter glo assay while 
proliferation was measured using the cyquant NF Cell Proliferation Assay. Apoptosis 
was analyzed via caspase glo R 3/7 assay. The cell viability for MDA-MB-468 cell 
line started to decline to 85% at dose 20µM of cisplatin and 75% at 25µM of 
cisplatin while viability in MCF-7 cell lines was reduced to 91% in the highest dose.  
Cisplatin showed anti proliferation effect for both cell lines started from the lowest 
concentration of the drug 5µM in MDA-MB-468 cell lines and at concentration of 
15µM for MCF-7 cell line. MDA-MB-468 showed changes in cell morphology at the 
dose of 25µM representing that small numbers of cells were damaged and disturbed 
in cell shape while MCF-7 showed no changes in cell morphology under the light 
microscope.  Cisplatin at 25µM did not induce apoptosis in MDA-MB-468 cell line 
in contrast with the control drug taxol at 50nM which induced apoptosis in MDA-
MB-468 cell line.  It can be concluded that cisplatin inhibits cell growth in a dose 
dependent manner and subsequent cytotoxicity resulting in morphological changes of 
the cancer cells, obvious reduction in cell viability and proliferation. Based on the 
findings, it can be concluded that cisplatin may induce differentiation in TNBCs. 
However, more investigations are needed to confirm its ability to induce 





Kanser payudara tiga ganda negatif (TNBC) adalah kumpulan khas tumor 
payu dara yang dicirikan oleh kekurangan mengekspresikan reseptor hormone 
termasuk estrogen (ER) dan progesteron (PGR) serta reseptor 2 faktor pertumbuhan 
epidermis manusia (HER2). Kanser payudara subjenis ini adalah berisiko tinggi 
dengan kewujudan sel-sel stem kanser payu dara (BCSCs) yang dianggap 
menjadikannya lebih agresif dan sukar untuk diubati. Dalam kajian in vitro ini, kesan 
cisplatin sebagai salah satu ubat antikanser platinum dalam dua bahagian sel kanser 
payu dara yang berbeza, yang mewakili tiga ganda negatif (MDA-MB-468) dan 
hormon positif Luminal A (MCF-7) subjenis kanser payu dara telah diperiksa. 
Cisplatin telah digunakan dalam lima kepekatan yang berbeza iaitu 5, 10, 15, 20 dan 
25μM, dan daya maju sel diukur dengan menggunakan ‗celltiter glo assay‘ manakala 
percambahan diukur dengan menggunakan ‗cyquant NF Cell Proliferation Assay‘. 
Apoptosis dianalisis melalui ‗caspaseglo R 3/7assay‘. Dayamaju sel bagi bahagian 
sel MDA-MB-468 mula merosot kepada 85% pada dos 20μM cisplatin dan 75% 
pada dos 25µM cisplatin, manakala dayamaju sel bagi bahagian sel MCF-7 telah 
merosot kepada 91% pada dos ubat yang tertinggi. Cisplatin menunjukkan kesan anti 
percambahan untuk kedua-dua bahagian sel bermula dari kepekatan ubat yang paling 
rendah, 5mM untuk bahagian sel MDA-MB-468 dan 15µM untuk bahagian sel 
MCF-7. Cisplatin pada kepekatan 25µM tidak mendorong apoptosis pada kedua-dua 
bahagian sel, berbeza dengan taxol pada 50µM yang mendorong apoptosis dalam 
bahagian sel MDA-MB-468. Dapat disimpulkan bahawa cisplatin menghalang 
pertumbuhan sel dengan cara yang bergantung kepada dos dan cytotoxicity 
seterusnya menyebabkan perubahan morfologi kepada sel-sel kanser, pengurangan 
ketara dalam dayamaju dan percambahan sel. Berdasarkan penemuan ini, dapat 
disimpulkan bahawa cisplatin boleh menyebabkan pembezaan dalam TNBCs. 
Walaubagaimanapun, siasatan yang lebih lanjut diperlukan untuk mengesahkan 
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1.1 Background of the Study 
Breast cancer is a malignant tumor that begins in the cells of the breast (Aktas 
et al., 2009). A malignant tumor is a cluster of cancer cells that can grow into 
(invade) surrounding tissues or spread (metastasize) to distant areas of the body 
(Sobin et al., 2011).  Breast cancer is the main common diagnosed cancer in female 
both in the developed and less developed countries.  Accounting for 23%  of the 
overall new cancer patients and 14% worldwide, over 508 000 women died in 2011 
due to breast cancer (Eittah et al., 2014).  Death rates for breast cancer have steadily 
decreased in women since 1989, with larger decreases in younger than in older 
women.  The decrease in breast cancer fatality rates represents improvements in both 
early diagnosis and treatment (Siegel et al., 2015). 
Triple negative breast cancers (TNBC) are characterized as aggressive cancer 
with early visceral metastasis and subsequently poorer prognosis  (Fan et al., 2012).  
Most deaths occur in the first 5 years (Chacón and Costanzo, 2010).  TNBCs  lack 
important hormonal receptors (estrogen ER, progesterone and human epidermal 
growth factor2 receptor HER2) which are generally used as target therapy in these 
breast cancer subtype (Hastak et al., 2010).  Chemotherapy remains to be the simply 
probable therapeutic choice in the adjuvant or metastatic setting in TNBCs (Dangi 
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and Firodiya, 2012).  Several efforts are recently being undertaken to develop 
treatment for patients with triple negative tumor as there are no known targeted 
therapies.  Many therapeutics are used with different target agents including anti-
angiogenesis (drugs stop tumors from making new blood vessels), proliferation 
signaling targeting, DNA binding agent and DNA repair mechanisms which 
significantly affect the response to cytotoxic treatments (Crown et al., 2012; Dangi 
and Firodiya, 2012; O'shaughnessy et al., 2011). 
These tumors are known to contain high number of cancer stem cells (CSCs), 
which are difficult to be killed by chemotherapy, thus many attempts are focusing on 
the identification of targeted treatments that make this CSC population within the 
tumors more susceptible to chemotherapy (Hastak et al., 2010; Tiwary et al., 2011).  
Cisplatin chemotherapy regimens have shown promising anticancer affects in the 
treatment of difficult to treat cancers such as testicular, ovarian, cervical, gastric as 
well as small cell lung cancer (Bertolini et al., 2009; Dasari and Tchounwou, 2014; 
Koizumi et al., 2008).  Cisplatin has multiple mechanisms of action, the primary 
mechanism involves, interaction with DNA to form DNA adducts and which activate 
a number of signal transduction pathways.  Signal pathway including those involving 
ATR, p53, p73, MAPK and culminate in the activation of apoptosis (Fuertes et al., 
2003; Galluzzi et al., 2012).  
The platinum atom in cisplatin is known to form a divalent bond with the 
purine bases at N7, whereby the 1, 2 or 1, 3 intrastrand crosslinks take place and 
disrupt the DNA structure.  This intrastrand crosslink between two adjacent G 
residues has shown to be the major damage resulting causing cytotoxicity (Basu and 
Krishnamurthy, 2010; O'Brien and Brown, 2006).  The Cisplatin DNA adducts 
interfere with DNA replication and transcription but the mechanism of action still 
vague (O‘Brien and Brown, 2006; Basu and Krishnamurthy, 2010).  This research 
will focus on examining the anticancer effects of cisplatin on TNBC cells, by 
studying the effect of this drug on cell viability, proliferation and it‘s ability to 
induce apoptosis.  
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1.2 Problem Statement 
Among all the breast cancer subtypes, TNBCs accounts for approximately 
fifteen percent  of all types of breast cancers (Cleator et al., 2007).  It is associated 
with a worse prognosis due to lack of hormonal receptors (estrogen, progesterone 
and HER2) which leads to the ineffectiveness of hormonal therapies, leaving the 
chemotherapy as the only and most suitable treatment.  In addition, patients with 
TNBC have tumor recurrence and the majority of deaths occur in the first 3 and 5 
years following the primary treatment, respectively making the TNBC an invasive 
form of breast cancer which needs attention (Ovcaricek et al., 2011).  Although the 
TNBCs are specifically sensitive to cisplatin, the mechanism in which cisplatin 
induces anti-cancer effects in TNBCs are still unclear. 
1.3 Objectives of the Study 
Followings are the objectives proposed for this study: 
i. To determine the effects of cisplatin on the growth and morphology of 
the triple negative breast cancer cells. 
ii. To study the effect of cisplatin in  inducing apoptosis in triple negative 
breast cancer cells. 
1.4 Scope of Study 
In vitro anticancer studies at the cellular level including cell viability, 
proliferation and apoptosis assays were conducted in two human breast cancer cell 
lines using cisplatin (cDDP). 
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1.5 Significance of the Study 
This research focuses on the mechanism of action of cisplatin in TNBCs 
includes their effect on programmed cell death, as long as their cytotoxicity effects 
representing in cell viability and proliferation.  Furthermore, it assists matching 
patient with the target therapy and contributes to reduce recurrency rate, surgery 
(mastectomy) and lowering the number of fatality, since TNBCs is one of leading 
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